UBS Maintains Buy on Evolent Health, Lowers Price Target to $5
Evolent Health Inc Class A +8.58% Pre
Evolent Health Inc Class A EVH | 2.53 2.53 | +8.58% 0.00% Pre |
UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:
EVH) with a Buy and lowers the price target from $10 to $5.
